Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.41 |
| ▸ | PTGES | O14684 | 6/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594893 | 0.90 | LTB4R2 (0.42) | LTB4R2ALOX5PTGESAOC3PTGES2 | |
| SCHEMBL7593565 | 0.85 | LTB4R2 (0.43) | LTB4R2HCAR3 | |
| SCHEMBL7598805 | 0.83 | TSPO (0.43) | LTB4R2HCAR3 | |
| SCHEMBL7592924 | 0.81 | LTB4R2 (0.48) | LTB4R2HCAR3 | |
| SCHEMBL7590647 | 0.81 | MAPT (0.40) | LTB4R2HCAR3 | |
| SCHEMBL7591466 | 0.80 | LTB4R2 (0.43) | LTB4R2 | |
| SCHEMBL7596184 | 0.78 | LTB4R2 (0.39) | LTB4R2ALOX5AOC3PTGES2BCL2 | |
| SCHEMBL7591701 | 0.78 | LTB4R2 (0.41) | LTB4R2 | |
| SCHEMBL7595241 | 0.78 | PTGES (0.46) | ALOX5PTGES | |
| SCHEMBL7595231 | 0.77 | ALDH1A1 (0.37) | LTB4R2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | LTB4R2 1901/4885ALOX5 1265/4885PTGES 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.